Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
Pivotal Phase III study in patients with severe dermatological condition bullous pemphigoid (BP) planned to
Quarter
Kiromic BioPharma Reports Third Quarter 2020 Financial Results and Continued Corporate Progress
HOUSTON–(BUSINESS WIRE)–Nov 30, 2020– Kiromic BioPharma (“the Company”) (NASDAQ: KRBP), a pre-clinical stage biotechnology company